Fresenius Medical Care Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Helen Giza

İcra Kurulu Başkanı

€5.5m

Toplam tazminat

CEO maaş yüzdesi	30.1%
CEO görev süresi	5yrs
CEO sahipliği	0.005%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Helen Giza'un ücretlendirmesi Fresenius Medical Care'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€659m
Jun 30 2024	n/a	n/a	€530m
Mar 31 2024	n/a	n/a	€484m
Dec 31 2023	€6m	€2m	€499m
Sep 30 2023	n/a	n/a	€450m
Jun 30 2023	n/a	n/a	€596m
Mar 31 2023	n/a	n/a	€602m
Dec 31 2022	€3m	€1m	€673m
Sep 30 2022	n/a	n/a	€763m
Jun 30 2022	n/a	n/a	€806m
Mar 31 2022	n/a	n/a	€878m
Dec 31 2021	€2m	€855k	€969m
Sep 30 2021	n/a	n/a	€918m
Jun 30 2021	n/a	n/a	€998m
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€2m	€855k	€1b
Sep 30 2020	n/a	n/a	€1b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€1b
Dec 31 2019	€2m	€108k	€1b

Tazminat ve Piyasa: Helen 'ın toplam tazminatı ($USD 5.76M ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.66M ).

Tazminat ve Kazançlar: Helen 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Helen Giza (56 yo)

5yrs

Görev süresi

€5,528,000

Tazminat

Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Helen Giza	Chair of Management Board & CEO	5yrs	€5.53m	0.0047% € 580.2k
Martin Fischer	CFO & Member of the Management Board	1.1yrs	€887.00k	Veri yok
Franklin Maddux	Global Chief Medical Officer & Member of Management Board	4.8yrs	€3.13m	0.0062% € 766.1k
Katarzyna Mazur-Hofsab	CEO of Care Enablement & Member of Management Board	2.8yrs	€3.71m	0.0039% € 479.8k
Craig Cordola	CEO of Care Delivery & Member of Management Board	less than a year	Veri yok	Veri yok
Dominik Heger	Executive VP and Head of Investor Relations	no data	Veri yok	Veri yok
Jorg Haring	Global Head of Legal	less than a year	Veri yok	Veri yok
Joachim Weith	Senior Vice President of Corporate Communications & Governmental Affairs	no data	Veri yok	Veri yok
Gail-Suzanne Brown	Senior Vice President of Research & Development	no data	Veri yok	Veri yok
Glenn Slater	Senior Vice President of Manufacturing and Supply Chain Operations	no data	Veri yok	Veri yok
Wolfgang Kummerle	Senior Vice President - Quality Management International	no data	Veri yok	Veri yok
Thomos Dimt	Executive Vice President of Western Europe & Nephrocare Coordination EMEALA	no data	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: FMED 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shervin Korangy	Independent Member of Supervisory Board	less than a year	€20.00k	Veri yok
Michael Sen	Chairman of the Supervisory Board	1.3yrs	€444.00k	Veri yok
Marcus Kuhnert	Independent Member of Supervisory Board	less than a year	€21.00k	Veri yok
A. Sorensen	Independent Member of Supervisory Board	3.5yrs	€151.00k	Veri yok
Stefanie Balling	Employee Representative Deputy Chairwoman of the Supervisory Board	less than a year	Veri yok	Veri yok
Sara Hennicken	Member of Supervisory Board	less than a year	€158.00k	Veri yok
Frank Prescher	Employee Representative Member of Supervisory Board	less than a year	Veri yok	Veri yok
Regina Karsch	Employee Representative Member of the Supervisory Board	less than a year	Veri yok	Veri yok
Manuela Grabo	Employee Representative Member of the Supervisory Board	less than a year	Veri yok	Veri yok
Ralf Erkens	Employee representatives Member of the Supervisory Board	less than a year	Veri yok	Veri yok
Beate Habdenteufel	Employee representatives Member of the Supervisory Board	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FMED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Fresenius Medical Care Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024

Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery

Fresenius Medical Care Announces Executive Changes

Fresenius Medical Care AG & Co. KGaA Announces CEO Changes

Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023

Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office

Recent updates

Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025

Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025

Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025

Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings released: EPS: €0.24 (vs €0.29 in 1Q 2023)

Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024

Dividend increased to €1.19

Dividend increased to €1.19

Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device

Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024

Dividend increased to €1.19

Dividend increased to €1.19

Full year 2023 earnings released: EPS: €1.70 (vs €2.30 in FY 2022)

Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023

Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024

Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S

Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government

Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023

New minor risk - Earnings quality

Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024

An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME)

Third quarter 2023 earnings released: EPS: €0.29 (vs €0.78 in 3Q 2022)

New major risk - Financial position

Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024

Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery

Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset

Investor sentiment deteriorates as stock falls 19%

Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: €0.48 (vs €0.50 in 2Q 2022)

An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).

Fresenius Medical Care Announces Executive Changes

Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates

Upcoming dividend of €1.12 per share at 2.6% yield

Full year 2022 earnings released: EPS: €2.30 (vs €3.31 in FY 2021)

Fresenius Medical Care AG & Co. KGaA Announces CEO Changes

Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023

Third quarter 2022 earnings released: EPS: €0.78 (vs €0.93 in 3Q 2021)

Fresenius Medical Care AG & Co. KGaA to Report Q2, 2023 Results on Aug 02, 2023

Second quarter 2022 earnings released: EPS: €0.50 (vs €0.75 in 2Q 2021)

Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022

Investor sentiment deteriorated over the past week

Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022

Fresenius Medical Care AG & Co. KGaA to Report Q3, 2022 Final Results on Nov 09, 2022

First quarter 2022 earnings released: EPS: €0.54 (vs €0.85 in 1Q 2021)

Upcoming dividend of €1.35 per share

Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office

Fresenius Medical Care AG & Co. KGaA Proposes Dividend, Due on 17 May 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius Medical Care Ag & Co. Kgaa Provides Earnings Forecast for the Year 2022

Fresenius Medical Care AG & Co. KGaA Launches New Mobile App to Empower and Engage Nurses

Third quarter 2021 earnings released: EPS €0.93 (vs €1.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.75 (vs €1.20 in 2Q 2020)

Independent Member of Supervisory Board has left the company

Fresenius Medical Care Approves Dividend for the Fiscal Year 2020

Upcoming dividend of €1.34 per share

First quarter 2021 earnings released: EPS €0.85 (vs €0.95 in 1Q 2020)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş